Annotated Medicine and Device Lists

Filgrastim

Injection 48 million IU/ml Injection 30 million IU/ml Injection 120 micrograms/0.2 mL in pre-filled syringe. Injection 300 micrograms/0.5 mL in pre-filled syringe. Injection 480 micrograms/0.8 mL in pre-filled syringe Injection 480 micrograms/1.6 mL in 1.6 mL vial

This medicine is present in:

List	Section	Observation
Chile	Essential and Prioritized Medications	No observations

This medicine is present in:

List	Section	Observation
Chile	Essential and Prioritized Medications	No observations

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Others observations: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Others observations: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Others observations: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

This medicine is present in:

List	Section	Observation
WHO Model List of Essential Medicines (2021)	8.2.3 Immunomodulators	Others observations: Including quality-assured biosimilars. − Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy. − Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy − To facilitate administration of dose dense chemotherapy regimens

Information Resources: Filgrastim

No information available